PRELIMINARY SCIENTIFIC PROGRAM As of December 28, 2017 Wednesday, 14 February 2018 14:30-16:00 INDUSTRY WORKSHOP INDUSTRY WORKSHOP INDUSTRY WORKSHOP 16:15-17:45 INDUSTRY WORKSHOP INDUSTRY WORKSHOP INDUSTRY WORKSHOP 18:00-19:00 OPENING CEREMONY Moshe Phillip - Opening Remarks Thomas Danne Beyond A1c: Consensus on CGM Outcomes 19:00-20:00 Networking Reception in the Exhibition Area
Thursday, 15 February 2018 08:00-09:30 PLENARY SESSION (1) COPING WITH GLUCOSE VARIABILITY Stephanie Amiel Reversibility of Brain Changes in Satish Garg - Role of Concentrated Insulins in Care Bruce Bode - Review of Ultra-Rapid Acting Insulins Jennifer Sherr - Nasal Glucagon: an alternative innovative needle free approach for the treatment of severe hypoglycemia 09:30-10:00 10:00-10:30 10:30-12:00 12:00-13:00 13:00-14:30 Lunch Break SESSION (2) GLUCOSE METRICX: BEYOND HbA1c SESSION (3) S OF START-UP COMPANIES SESSION (4) NEXT GENERATION SOLUTIONS INDUSTRY WORKSHOP INDUSTRY WORKSHOP Irl Hirsch - Time in Ranges or HbA1c? Richard Bergenstal - Glucose Variability: Which Measures Are Clinically Meaningful? Hans DeVries - Glycation Gap: Does It Exist? Simon Heller - Hypoglycemia and Mortality: A Causal Relationship? Join this session to meet the start-up finalists and unpack their ideas. Judged by ATTD s expert panel as the most exciting innovations from the largest number of entries we have ever had, this session is a must for the investor community and those with an eye out for the next big thing. David Klonoff - Trends in Digital Health for Francis Doyle III - Dealing with Patient and Device Uncertainty in the Artificial Pancreas: Multi-zones, Adaptation, and Trust Indices Eyal Dassau Next Generation Automated Insulin Delivery: On- Body Ecosystem for Automated Insulin Delivery in Type 1 Neal Kaufman - Digital Self- Management Support
14:30-15:00 15:00-16:30 16:40-18:00 SESSION (5) DEBATE: PUMP V. SENSOR WHAT IS MORE IMPORTANT? SESSION (6) IT IS NOT JUST ABOUT GLUCOSE Interventions: Foundational to Improving Health Outcomes SESSION (7) ACCESS TO NOVEL TECHNOLOGY SESSION 1 SESSION 2 Lalantha Leelarathna Pumps Hans DeVries Sensors Discussion Lori Laffel Aligning Patient Expectations with Automated Insulin Delivery System: Understanding Patients Reported Outcomes Katharine Barnard Supporting Healthcare Professionals: Finding the QoL Balance Pratik Choudhary Understanding the Relationship Between Distress and Metabolic Outcomes Irl Hirsch - Cost of Medications Vs. Outcomes: Is there an End George Grunberger We Have the Technology, We Have the Data, and Now What? Aaron Kowalski - The Role of Patients in Increasing Access to New Treatments Henk J. Veeze - Value Based Health Care / Diabeter Experience
Friday, 16 February 2018 08:00-08:50 09:00-10:00 MORNING SYMPOSIUM SESSION (8) CLOSING THE LOOP - NIH- FUNDED AP RESEARCH EFFORTS Boris Kovatchev - The International Closed-Loop (idcl) Trial Roman Hovorka - Day and Night Closed-loop in Young People with Type 1 (DAN05) Richard Bergenstal - A Crossover Study Comparing Two Automated Insulin Delivery System Algorithms in Adolescents and Young Adults with Type 1 Steven Russell - Bionic Pancreas Treats Adults with Type 1 SESSION (9) BIOTECHNOLOGY AND DIABETES Desmond Schatz Update on Worldwide Efforts to Prevent Type 1 Mark Sperling: Posttransplant in Children and Adolescents Lorenzo Piemonti - Beta Cell Replacement, Where Are We? SESSION (10) 09:00-09:30 Stayce Beck Moving Forward With Regulatory Approval INDUSTRY WORKSHOP 09:40-10:00 INDUSTRY WORKSHOP SESSION 3 SESSION (11) S OF START-UP COMPANIES 10:00-10:30 10:30-12:00 12:00-13:00 13:00-14:30 Lunch Break PLENARY SESSION (12) ATTD YEARBOOK Satish Garg/Irl B. Hirsch -Self-monitoring of Blood Glucose Bruce Bode/Tadej Battelino - Continuous Glucose Monitoring John Pickup - Insulin Pumps
Eyal Dassau/Revital Nimri - Closing the Loop Jan Bolinder/Thomas Danne/Lutz Heinemann - New Insulins, biosimilars, and Insulin Therapy Neal Kaufman - Using Digital Health Technology to Prevent and Treat, Helen Murphy - Technology and Pregnancy Desmond Schatz/Natasa Bratina - Immune Intervention for type 1 diabetes, Michael C. Riddell - Advances in Exercise Physical Activity and Mellitus, Shlomit Shalitin/David Maahs - Technology and Therapy in the Pediatric Age Group Alon Liberman/Katharine Barnard - Technology and the Human Factor Satish Garg - New Medications for the Treatment of 14:30-15:00 15:00-16:30 16:40-18:00 SESSION (13) NUTRITION AND FOOD TECHNOLOGIES SESSION (14) MAJOR OUTCOME STUDIES: THE HypoDE STUDY SESSION (15) CLINICAL DECISION SUPPORT SYSMTESM (ADVISORS) SESSION (16) ISPAD SESSION CHALLENGES WITH DIABETES TECHNOLOGY IN PEDIATRICS INDUSTRY WORKSHOP Michal Gillon Introduction Eran Segal - Personalized Medicine Approaches for Treatment of Based on Gut Microbiota Stavroula Mougiakakou - The future role of machine learning and computer vision in carbohydrate estimation for diabetic patients Guido Freckmann - Study Design and Execution Lutz Heinemann - Results Norbert Hermanns - Patient Related Outcomes Hans DeVries - Independent Commentary Deborah Mullen Using Glucose Profiles (AGP) for Shared Decision Making Mark Clements Machine Learning to Improve T1D Care Revital Nimri - Automated Decision Support System for Medical Team Who Treats Patients with Type 1 Ragnar Hanas - Technology in the <6-year-old Population Laurel Messer - Practical Issues in School with Technology
Andrea Scaramuzza - Efficacy of an APP to Count Carbs and Beyond to Limit the Postmeal Glucose Rise in Children with Type 1 Boris Kovatchev - Decision Support Systems Eda Cengiz - Technology in Adolescents and Young Adults Eduardo Calliari - Technology in Developing Countries
Saturday, 17 February 2018 08:30-10:00 10:00-10:30 10:30-12:00 SESSION (17) DEBATE: CAN DIGITAL HEALTH REPLACE THE HCP? Revital Nimri Pro Lori Laffel con Discussion SESSION (20) PUMPS, SENSORS & FGM WHERE DO WE GO? SESSION (18) DIABETESINDIA SYMPOSIUM S. R. Aravind - Evolution of Technologies in India Manoj Chawla - Use of Insulin Pump Therapy in India - The Changing Perspective Jothydev Kesavadev - SMBG and Virtual Consultation DTMS (R): 20 Years' Experience Banshi Saboo - CGM & AGP - How to Reap Its Benefit From Busy Clinics in India? SESSION (21) PRACTICAL CLOSED LOOP THERAPY: EDUCATION AND IMPLEMENTATION SESSION (19) DIABETES TECHNOLOGY FOR TYPE 2 DIABETES Yves Reznik - Insulin Pump and CGM Eric Renard - Artificial Pancreas Marc Breton - Decision Tools SESSION (22) TURKISH DIABETES TECHNOLOGY GROUP: GLYCEMIC VARIATION IN DIABETES CONTROL SESSION 4 SESSION 5 SESSION 6 John Pickup - What Determines the Effectiveness of Insulin Pump Therapy: Towards Precision Technology? Jan Bolinder - Review of Flash Glucose Monitoring Benefits vs Capillary and vs CGM Nebojsa Lalic - Insulin Pump Treatment in Type 2 : Laurel Messer - Artificial Pancreas: Managing Expectations, Misconceptions and Preparing Patients for Success Sarah Biester- Train the Trainer: What do Clinicians Need to Understand About CL Technology? Damla Göksen - Glycemic Variability vs Glucose Control in Children Selçuk Dağdelen - Glycemic Variability vs Glucose Control in Adults Eda Cengiz - New Short and Long Acting Insulin Analogues and Glycemic Variability
Impact on Insulin Resistance and Related Metabolic Parameters Riccardo Bonfanti - CGM Standalone in Children Using Multiple Daily Injections Jennifer Sherr - Patients Perspective on Closed- loop Technology Barbara Murn Berkopec - Addressing Barriers to CGM and CL Therapies 12:00-13:00 13:00-13:05 13:05-13:45 PLENARY SESSION (23) SURGICAL AND PHARMACEUTICAL SOLUTIONS FOR OBESE PEOPLE WITH TYPE 2 DIABETES Francesco Rubino - Insulin-independent Mechanisms of Action of Bariatric/Metabolic Surgery Walter Pories The Downside to Metabolic (bariatric) Surgery Timo Müller Novel Pharmacological Approaches to Treat Obesity and T2 CLOSING REMARKS AND FAREWELL Tadej Battelino Farewell refreshments in the Exhibition Area